FDA panel to review Edwards SAPIEN valve next month

Edwards Lifesciences has announced that an FDA advisory panel is scheduled to review the company's PMA application for its Edwards SAPIEN transcatheter heart valve on July 20. Edwards submitted the application last fall based on data from the inoperable cohort (Cohort B) of The PARTNER Trial, for approval of this therapy in the treatment of inoperable patients with severe aortic stenosis.
Edwards Lifesciences release

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.